the years 1990 to 1991; a comparable patte was seen when the analysis was confined those countries that had begun testing befc
1989.
No attempt was made in this survey estimate the precise risk resulting from ea prediction, but of the 1257 test results givini significant risk alteration, 460 (36-6%) gavc raised risk, while in 797 (63 4) the risk M reduced. In 249 cases (16-5% of the over total), no risk alteration was possible.
Discussion
It is clear from the data given here that pi symptomatic testing for HD has now becor an established service in many countries, wi Australia  21  47  21  89  4  4  Belgium  8  17  16  41  3  1  Canada  88  137  67  292  15  3  Denmark  21  18  12  51  1  1  Finland  2  8  0  10  1  1  France  10  15  8  33  1  1  Germany   7  21  8  36  2  2  Greece  11  28  15  54  1  1  Holland  50  77  9  136  1  1  Italy  15  45  9  69  2  2  Japan  9  23  22  54  1  1  Norway  11  22  8 It is hoped that continued collection and analysis of these international data will be possible and that they will prove of value for those planning programmes of presymptomatic testing not only for HD, but for other important genetic disorders of later life for which presymptomatic testing will become possible. Thanks are due to all the collaborating members from the various countries named in the appendix, and to the many others involved in the clinical and laboratory aspects of the testing programmes, as well as to the International Huntington's Association and World Federation of Neurology Research Committee for their encouragement to collect the data.
